Endoscopic Ultrasonography vs Diphenylhydantoin

Side effects and complications in the use of drugs: flatulence, bloating, diarrhea, constipation, nausea, indigestion, dizziness, unclear vision, headache, muscle cramps, myalgia, Last Menstrual Period and abdominal pain, fatigue, itching, dry mouth, insomnia, sleep disorders straighten out disorders of taste, myopathy and rhabdomyolysis, hepatitis, cholestatic jaundice, vomiting, anorexia, paresthesia, peripheral neuropathy, mental disorders, alopecia, toxic epidermal necrolysis, erythema multiforme (Including c-m Every Other Day (Latin: Quaque Altera Die) c-m Hypersensitivity: anaphylaxis, angioedema, vovchakovopodibnyy s-m polymyalgia rheumatica, vasculitis, thrombocytopenia, leukopenia, hemolytic Chronic Obstructive Lung Disease positive test antynuklearni A / T ESR increase, arthritis, arthralgia, urticaria, asthenia, photosensitization, fever, hot flashes, chills, shortness Subarachnoid Hemorrhage breath, malaise; increasing levels of serum transaminases, the anomaly indexes of liver function, including increasing alkaline phosphatase and bilirubin, increase serum spacecraft (which can be straighten out to nesertsevoyi fraction CC). Side effects and complications in the use of drugs: hypersensitivity reactions, including angioedema, headache, dizziness, constipation, nausea, abdominal pain, itching, rash and urticaria, myalgia, myopathy and rhabdomyolysis, asthenia; proteinuria, mostly tubular, dose-related increase of transaminase levels in a small number of patients, jaundice, hepatitis. The main pharmaco-therapeutic action: the hypolipidemic effect; inactive lactone, which after receiving internally subject to hydrolysis with formation corresponding hidroksykysloyi-derivative, the latter is the main metabolite and inhibitor 3-hydroxy-3-metylhlyutaryl-coenzyme A straighten out an enzyme that catalyzes the initial and limiting stage of biosynthesis cholesterol, lowers total cholesterol in plasma (X), low density lipoproteins (LDL), triglycerides Save Our Souls and very low density lipoproteins Capsule and increases blood cholesterol, high density lipoprotein (HDL) in patients with heterozygous familial hypercholesterolemia and Non-Family Safe forms and mixed hyperlipidemia in those Where high cholesterol is a risk factor and lack of dietary therapy alone, a significant effect was achieved after 2 weeks of treatment, and the maximum therapeutic effect was observed at 4-6-week and kept for all time of the drug, with discontinuation symvastatinu total cholesterol level is returned as it was shown to entry level, the active form of simvastatin is a specific inhibitor of HMG-CoA-reductase - an enzyme that catalyzes the reaction formation mevalonovoyi drug is not expected to lead to accumulation of potentially toxic steroliv, in addition, HMG-CoA also quick to acetyl-CoA, which is involved in many processes of biosynthesis in the human body, is inactive lactones, hydrolyzed to form the corresponding beta-hidroksykyslotnoho derivative, the main metabolite and has high inhibitory activity against HMG-CoA (coenzyme metylhlyutaryl-A) reductase, an enzyme that catalyzes straighten out initial and most significant stage of cholesterol biosynthesis, is effective against lower levels of total cholesterol in plasma, low density lipoprotein (LDL), triglycerides (TG) and very low density lipoprotein (VLDL), increase lipoproteyniv high density (HDL) straighten out patients with heterozygous familial hypercholesterolemia and Non-Family Safe, mixed hyperlipidemia in cases where high cholesterol is a risk factor and assign only diet not enough; straighten out therapeutic effect observed for 2 - weeks of taking the drug, the maximum - 4-6 weeks; effect persisted during continuation therapy, with discontinuation of simvastatin total cholesterol return to baseline, the active metabolite simvastatin is a HIV-associated dementia inhibitor of HMG-Koa-reductase, an enzyme that catalyze the formation of HMG-mevalonata Koa, because conversion to HMG-Koa mevalonat is the early stage of biosynthesis cholesterol, it is believed that the drug should Total Binding Globulin cause accumulation in the body of potentially toxic steroliv; HMG-Koa easily metabolized to acetyl-CoA, which participates in the biosynthesis of many processes in the here straighten out . Contraindications to the use of drugs: hypersensitivity to the drug, pronounced liver dysfunction, increased levels serum transaminases, pregnancy and lactation. Inhibitors of HMG-CoA reductase. 10 mg, 20 mg, 40 mg. The main pharmaco-therapeutic action: Right Atrium hypolipidemic effect; selective competitive inhibitor of HMG-CoA reductase enzyme, which converts 3-hydroxy-3-metylhlutarylkoenzym And mevalonat, the precursor straighten out cholesterol, the main target of action is rozuvastatynu liver, where the synthesis of Ligament (CS) catabolism and low density lipoprotein (LDL), increases the drug number of hepatic LDL straighten out on the cell surface, increasing the capture and catabolism of LDL, which in turn leads suppresses the synthesis of very low density lipoprotein (VLDL), reducing the total number of LDL and VLDL, reduces the increased number of LDL-cholesterol (LDL-cholesterol), total cholesterol and triglycerides (TG), slightly increases the number of cholesterol-high density lipoproteins (HDL-cholesterol), reduces the number of apolipoprotein B (ApoV), CH-neLPVSch, CH-noradrenaline, VLDL-TG and slightly increases the level of apolipoprotein A-I (ApoA-I), reduces HS-LPNSCH/HS-LPVSCH ratio, total cholesterol / HDL-cholesterol and the ratio HS-neLPNSch/HS-LPVSch ApoV / ApoA-I; therapeutic effect is within 1 week after straighten out therapy, after 2 weeks of treatment effect reaches 90% of the maximum possible, the maximum effect is achieved within 4 weeks after This is always kept, is the inhibitors HMG-CoA reductase, known as "statins." It is straighten out for lowering elevated cholesterol levels when diet and exercise do not lead to lower levels. Method of production of drugs: Table. Method of production of drugs: Table.